News
Previously untreatable lung cancer patients offered new therapy
The National Institute for Health and Care Excellence (NICE) has published a final appraisal document recommending Amgen’s Lumykras (sotorasib) for use within the Cancer Drugs Fund, for treating a type of lung cancer in adults whose disease has progressed or who cannot tolerate chemotherapy.